Abstract
We have conducted four prospective multicenter studies for acute promyelocytic leukemia (APL) using oral 45 mg/m2 all-trans retinoic acid (ATRA) daily. The first three studies were for relapsed/refractory APL, and the fourth study for newly diagnosed APL. In the first study with ATRA alone, 18 (82%) of 22 evaluable patients achieved complete remission (CR). Initial peripheral leukemia cell counts were significantly less in the CR cases (p
| Original language | English |
|---|---|
| Journal | Leukemia |
| Volume | 8 |
| Issue number | SUPPL. 3 |
| Publication status | Published - 1994 |
| Externally published | Yes |
Fingerprint
ASJC Scopus subject areas
- Cancer Research
- Hematology
Cite this
All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan. / Ohno, R.; Ohnishi, K.; Takeshita, A.; Tanimoto, M.; Murakami, H.; Kanamaru, A.; Asou, N.; Kobayashi, T.; Kuriyama, K.; Ohmoto, E.; Sakamaki, H.; Tsubaki, K.; Hiraoka, A.; Yamada, O.; Oh, H.; Furusawa, S.; Matsuda, S.; Naoe, T.
In: Leukemia, Vol. 8, No. SUPPL. 3, 1994.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - All-trans retinoic acid therapy in relapsed/refractory or newly diagnosed acute promyelocytic leukemia (APL) in Japan
AU - Ohno, R.
AU - Ohnishi, K.
AU - Takeshita, A.
AU - Tanimoto, M.
AU - Murakami, H.
AU - Kanamaru, A.
AU - Asou, N.
AU - Kobayashi, T.
AU - Kuriyama, K.
AU - Ohmoto, E.
AU - Sakamaki, H.
AU - Tsubaki, K.
AU - Hiraoka, A.
AU - Yamada, O.
AU - Oh, H.
AU - Furusawa, S.
AU - Matsuda, S.
AU - Naoe, T.
PY - 1994
Y1 - 1994
N2 - We have conducted four prospective multicenter studies for acute promyelocytic leukemia (APL) using oral 45 mg/m2 all-trans retinoic acid (ATRA) daily. The first three studies were for relapsed/refractory APL, and the fourth study for newly diagnosed APL. In the first study with ATRA alone, 18 (82%) of 22 evaluable patients achieved complete remission (CR). Initial peripheral leukemia cell counts were significantly less in the CR cases (p
AB - We have conducted four prospective multicenter studies for acute promyelocytic leukemia (APL) using oral 45 mg/m2 all-trans retinoic acid (ATRA) daily. The first three studies were for relapsed/refractory APL, and the fourth study for newly diagnosed APL. In the first study with ATRA alone, 18 (82%) of 22 evaluable patients achieved complete remission (CR). Initial peripheral leukemia cell counts were significantly less in the CR cases (p
UR - http://www.scopus.com/inward/record.url?scp=0028568378&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028568378&partnerID=8YFLogxK
M3 - Article
VL - 8
JO - Leukemia
JF - Leukemia
SN - 0887-6924
IS - SUPPL. 3
ER -